GlassScriptPhysician profile
Jillian Sullivan
NPI 1639423734
$2,805.23
in general payments reported to CMS, 2019-2025
27 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $386 · 2023: $172 · 2024: $622 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.81 | 2024-2025 | |
| Novo Nordisk INC | $310.49 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $281.56 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.32 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $195.01 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $149.50 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $148.33 | 2024-2025 | Veozah |
| Corcept Therapeutics | $111.02 | 2021-2022 | |
| Pfizer INC. | $110.21 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $102.77 | 2025 | Winrevair |
| Exact Sciences Corporation | $99.48 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $84.04 | 2024 | Injectafer |
| Janssen Biotech, INC. | $65.37 | 2021 | |
| Amgen INC. | $61.40 | 2025 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $46.91 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.42 | 2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $29.24 | 2021 | |
| Inspire Medical Systems, INC. | $23.72 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $23.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.94 | 2023 | |
| Amneal Pharmaceuticals LLC | $20.55 | 2025 | Unithroid |
| Ardelyx, INC. | $20.07 | 2025 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $19.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.27 | 2022 | |
| Eisai INC. | $17.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.44 | 2022 | |
| Currax Pharmaceuticals LLC | $13.46 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.